What is the appropriate treatment for overt hypothyroidism and hyperthyroidism, considering disease severity, patient age, weight, cardiac status (e.g., coronary artery disease or heart failure), pregnancy plans, and any comorbid conditions?

Thyroid Treatment: Hypothyroidism and Hyperthyroidism

Overt Hypothyroidism Treatment

Levothyroxine monotherapy is the standard treatment for overt hypothyroidism, with dosing and initiation strategy determined by age, cardiac status, and disease severity 1, 2, 3.

Initial Dosing Strategy

For patients under 70 years without cardiac disease:

• Start with full replacement dose of approximately 1.6 mcg/kg/day 1
• This approach rapidly normalizes thyroid function and prevents cardiovascular dysfunction 1

For patients over 70 years OR with cardiac disease (coronary artery disease, heart failure):

• Start with 25-50 mcg/day and titrate slowly by 12.5-25 mcg every 6-8 weeks 1, 2, 3
• Rapid normalization can unmask cardiac ischemia, precipitate myocardial infarction, or trigger life-threatening arrhythmias 1
• Elderly patients with coronary disease are at highest risk of cardiac decompensation even with therapeutic doses 1

Critical Safety Precaution

Before initiating levothyroxine, rule out adrenal insufficiency by measuring morning cortisol and ACTH 1, 2:

• Starting thyroid hormone before corticosteroids can precipitate life-threatening adrenal crisis 1, 2
• If adrenal insufficiency is present, start hydrocortisone (20 mg morning, 10 mg afternoon) at least one week before levothyroxine 1
• This is especially critical in patients with suspected central hypothyroidism or autoimmune disease 1, 2

Monitoring Protocol

• Recheck TSH and free T4 every 6-8 weeks during dose titration 1
• Target TSH: 0.5-4.5 mIU/L with normal free T4 1, 2
• Once stable, monitor TSH every 6-12 months 1
• Free T4 helps interpret ongoing abnormal TSH during therapy, as TSH may take longer to normalize 1

Common Pitfalls

Approximately 25% of patients on levothyroxine are unintentionally overtreated with suppressed TSH 1:

• TSH <0.1 mIU/L increases risk of atrial fibrillation (3-5 fold), osteoporosis, fractures, and cardiovascular mortality 1
• If TSH <0.1 mIU/L: reduce dose by 25-50 mcg immediately 1
• If TSH 0.1-0.45 mIU/L: reduce dose by 12.5-25 mcg, especially in elderly or cardiac patients 1

---

Subclinical Hypothyroidism Treatment

Treatment decisions for subclinical hypothyroidism (elevated TSH with normal free T4) depend on TSH level, symptoms, and patient-specific factors 1, 2.

TSH >10 mIU/L

Initiate levothyroxine regardless of symptoms 1, 2:

• This threshold carries approximately 5% annual risk of progression to overt hypothyroidism 1, 2
• Associated with cardiac dysfunction (delayed relaxation, abnormal cardiac output) and adverse lipid profiles 1
• Treatment may improve symptoms and lower LDL cholesterol 1
• Evidence quality: fair 1

TSH 4.5-10 mIU/L

Routine treatment is NOT recommended for asymptomatic patients 1:

• Randomized trials show no symptomatic benefit 1
• Evidence quality: fair 1

Consider treatment in specific situations 1, 2:

• Symptomatic patients (fatigue, weight gain, cold intolerance, constipation): 3-4 month trial with clear evaluation of benefit 1
• Pregnant women or planning pregnancy: treat any TSH elevation, targeting TSH <2.5 mIU/L in first trimester 1, 4, 5
• Positive anti-TPO antibodies: higher progression risk (4.3% vs 2.6% annually in antibody-negative patients) 1, 2
• Patients with goiter or infertility 2

Confirmation Before Treatment

Repeat TSH and free T4 after 3-6 weeks before starting therapy 1:

• 30-60% of elevated TSH values normalize spontaneously 1
• Exclude transient causes: acute illness, recent iodine exposure, recovery from thyroiditis, certain medications 1

---

Special Populations

Pregnancy

Maternal hypothyroidism requires aggressive treatment to prevent adverse outcomes 4, 5:

For women with pre-existing hypothyroidism:

• Increase levothyroxine by 25-50% immediately upon pregnancy confirmation 4
• Do NOT wait for TSH results—fetal harm can occur before maternal symptoms appear 4
• Target TSH <2.5 mIU/L in first trimester 4, 5
• Monitor TSH every 4 weeks until stable, then each trimester 4

Risks of inadequate treatment 4, 5:

• Preeclampsia, low birth weight, placental abruption, fetal death 4
• Permanent neurodevelopmental deficits in offspring 4, 5
• First trimester hypothyroidism specifically linked to cognitive impairment 4

For newly diagnosed hypothyroidism in pregnancy:

• Start levothyroxine immediately 5
• Maintain free T4 in high-normal range 4

Elderly Patients (>80 years)

For TSH 4.5-10 mIU/L with normal free T4:

• Observation is preferred over treatment 1
• Approximately 12% of individuals >80 years have TSH >4.5 mIU/L without thyroid disease 1
• Risks of overtreatment (atrial fibrillation, fractures) outweigh uncertain benefits 1

If treatment is indicated:

• Start at 25-50 mcg/day 1
• Consider slightly higher TSH targets (up to 5-6 mIU/L) to avoid overtreatment 1

Cardiac Comorbidities

For patients with heart failure, coronary artery disease, or atrial fibrillation:

• Start levothyroxine at 25-50 mcg/day regardless of age 1, 2
• Titrate by 12.5 mcg increments every 6-8 weeks 1
• Obtain ECG to screen for baseline arrhythmias 1
• Monitor closely for angina, palpitations, or worsening heart failure 1
• Consider more frequent monitoring (within 2 weeks) after dose adjustments 1

---

Hyperthyroidism Treatment

Treatment for overt hyperthyroidism includes antithyroid drugs, radioactive iodine, and surgery, with choice depending on etiology, severity, patient age, and pregnancy status 6, 7.

Graves Disease

Three treatment modalities are available 6, 7:

Antithyroid drugs (methimazole or propylthiouracil):

• First-line for inducing remission over 12-18 months 6
• Also used short-term before radioiodine or surgery to achieve euthyroid state 6
• Propylthiouracil is preferred in pregnancy (especially first trimester) 5
• Target: maintain free T4 in upper normal range during pregnancy 5
• Doses can be reduced in third trimester due to immune-suppressant effects of pregnancy 5

Radioactive iodine:

• Growing use as first-line therapy 6
• Well tolerated; main long-term risk is hypothyroidism 6
• Contraindicated in pregnancy and lactation 6
• Avoid pregnancy for 4 months after administration 6
• May worsen Graves ophthalmopathy (corticosteroid cover may reduce risk) 6

Surgery (subtotal or near-total thyroidectomy):

• Limited role in Graves disease 6
• Consider if radioiodine refused or large goitre causing compression symptoms 6
• Goal: cure pathology while maintaining euthyroidism 6

Toxic Nodular Goitre

Radioiodine is the treatment of choice 6:

• Antithyroid drugs will not cure toxic nodular goitre 6
• Surgery is alternative if radioiodine contraindicated 6

Subclinical Hyperthyroidism

Treatment recommended for high-risk patients 7:

• Age >65 years 7
• Persistent TSH <0.1 mIU/L 7
• Patients at risk for osteoporosis or cardiovascular disease 7

Thyroid Storm

Use standard drug series 8:

• Propylthiouracil or methimazole 8
• Saturated solution of potassium iodide or sodium iodide (alternatives: Lugol's solution, lithium) 8
• Dexamethasone 8
• Phenobarbital 8
• General supportive measures: oxygen, antipyretics, appropriate monitoring 8
• Treat perceived underlying cause 8
• Avoid delivery during thyroid storm unless deemed necessary 8

---

Key Monitoring Parameters

For all patients on levothyroxine:

• TSH is the most sensitive test (>98% sensitivity, >92% specificity) 1
• Monitor TSH every 6-8 weeks during titration 1
• Once stable, monitor every 6-12 months 1
• Adjust dose by 12.5-25 mcg increments based on TSH response 1

Red flags for overtreatment:

• Development of low TSH suggests overtreatment or recovery of thyroid function 1
• Reduce dose with close follow-up 1
• Prolonged TSH suppression increases risk for atrial fibrillation, osteoporosis, and cardiovascular mortality 1